Patent · US Active

Gene expression markers for predicting response to chemotherapy

US9605318B2 · kind B2 · utility

1Cited by

59References

18Claims

0Family size

Assignee

Genomic Health, Inc. · US

Inventors

Joffre B. Baker · Montara, US
Steven Shak · Burlingame, US
Luca Gianni · Milano, IT

Key dates

Filing date	Nov 8, 2010
Grant date	Mar 28, 2017
Priority date	—
Expiry date	Nov 3, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2474/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.